 Tilman Humpl
Concepts (412)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most Recent Publication
|
Publications by all authors
|
Concept score
|
Why?
|
|---|
| Hypertension, Pulmonary | 26 | 2019 | 219 | 5.430 |
Why?
| | Heart-Assist Devices | 12 | 2019 | 89 | 3.850 |
Why?
| | Cardiac Catheterization | 11 | 2019 | 320 | 2.390 |
Why?
| | Heart Defects, Congenital | 18 | 2019 | 1092 | 2.240 |
Why?
| | Risk Assessment | 10 | 2019 | 921 | 1.610 |
Why?
| | Extracorporeal Membrane Oxygenation | 10 | 2018 | 194 | 1.560 |
Why?
| | Critical Care | 3 | 2019 | 171 | 1.520 |
Why?
| | Body Weight | 2 | 2019 | 270 | 1.340 |
Why?
| | Heart Transplantation | 10 | 2015 | 412 | 1.330 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2019 | 229 | 1.250 |
Why?
| | Phosphodiesterase 5 Inhibitors | 2 | 2016 | 5 | 1.210 |
Why?
| | Cardiac Surgical Procedures | 9 | 2010 | 511 | 1.210 |
Why?
| | Pulmonary Artery | 8 | 2019 | 399 | 1.210 |
Why?
| | Heart Failure | 5 | 2019 | 163 | 1.210 |
Why?
| | Registries | 8 | 2019 | 459 | 1.200 |
Why?
| | Infant | 47 | 2019 | 9417 | 1.190 |
Why?
| | Vasodilator Agents | 6 | 2016 | 67 | 1.140 |
Why?
| | Piperazines | 5 | 2012 | 43 | 1.120 |
Why?
| | Heart Diseases | 4 | 2019 | 198 | 1.080 |
Why?
| | Female | 58 | 2019 | 22320 | 1.070 |
Why?
| | Child, Preschool | 45 | 2019 | 11371 | 1.060 |
Why?
| | Humans | 81 | 2019 | 37298 | 1.040 |
Why?
| | Child | 55 | 2019 | 16991 | 1.040 |
Why?
| | Lung Diseases | 4 | 2018 | 220 | 1.010 |
Why?
| | Male | 56 | 2019 | 21620 | 0.980 |
Why?
| | Infant, Newborn | 36 | 2019 | 5682 | 0.960 |
Why?
| | Retrospective Studies | 26 | 2019 | 5306 | 0.940 |
Why?
| | Pulmonary Wedge Pressure | 4 | 2016 | 13 | 0.930 |
Why?
| | Calcium Channel Blockers | 2 | 2016 | 35 | 0.890 |
Why?
| | Catheterization | 4 | 2013 | 139 | 0.890 |
Why?
| | Echocardiography | 9 | 2018 | 594 | 0.880 |
Why?
| | Endarterectomy | 1 | 2019 | 6 | 0.850 |
Why?
| | Peritoneovenous Shunt | 1 | 2019 | 4 | 0.850 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 23 | 0.840 |
Why?
| | Sulfones | 5 | 2012 | 28 | 0.830 |
Why?
| | Patient Admission | 1 | 2019 | 70 | 0.820 |
Why?
| | Vascular Diseases | 2 | 2018 | 47 | 0.810 |
Why?
| | Hemodynamics | 9 | 2015 | 402 | 0.810 |
Why?
| | Adolescent | 39 | 2019 | 12625 | 0.810 |
Why?
| | Familial Primary Pulmonary Hypertension | 7 | 2018 | 33 | 0.790 |
Why?
| | Follow-Up Studies | 15 | 2019 | 2649 | 0.790 |
Why?
| | Pulmonary Atresia | 2 | 2010 | 62 | 0.710 |
Why?
| | Health Information Systems | 1 | 2016 | 4 | 0.690 |
Why?
| | Vascular Resistance | 5 | 2012 | 77 | 0.690 |
Why?
| | Prognosis | 15 | 2019 | 1618 | 0.680 |
Why?
| | Survival Rate | 10 | 2019 | 755 | 0.660 |
Why?
| | Ventricular Function, Left | 2 | 2014 | 216 | 0.640 |
Why?
| | Oxygen Consumption | 8 | 2013 | 195 | 0.610 |
Why?
| | Recovery of Function | 2 | 2014 | 186 | 0.600 |
Why?
| | Tomography, X-Ray Computed | 5 | 2019 | 991 | 0.590 |
Why?
| | Pulmonary Veno-Occlusive Disease | 1 | 2014 | 52 | 0.590 |
Why?
| | Carotid Artery Injuries | 1 | 2013 | 4 | 0.580 |
Why?
| | Hospital Mortality | 3 | 2012 | 163 | 0.580 |
Why?
| | Brachiocephalic Trunk | 1 | 2013 | 13 | 0.580 |
Why?
| | Aneurysm | 1 | 2013 | 22 | 0.570 |
Why?
| | Heart Ventricles | 5 | 2018 | 496 | 0.570 |
Why?
| | Databases, Factual | 1 | 2016 | 377 | 0.570 |
Why?
| | Cardiac Output | 2 | 2013 | 75 | 0.570 |
Why?
| | Nitric Oxide | 4 | 2016 | 200 | 0.570 |
Why?
| | Indicator Dilution Techniques | 1 | 2013 | 8 | 0.560 |
Why?
| | Hernias, Diaphragmatic, Congenital | 4 | 2018 | 121 | 0.530 |
Why?
| | Exercise Test | 4 | 2011 | 165 | 0.530 |
Why?
| | Coronary Care Units | 1 | 2012 | 17 | 0.530 |
Why?
| | Vasoconstrictor Agents | 2 | 2012 | 37 | 0.520 |
Why?
| | Aorta | 5 | 2016 | 169 | 0.520 |
Why?
| | Patient Readmission | 1 | 2012 | 51 | 0.510 |
Why?
| | Treatment Outcome | 14 | 2015 | 4117 | 0.510 |
Why?
| | Prosthesis Design | 3 | 2015 | 95 | 0.470 |
Why?
| | Cor Triatriatum | 1 | 2010 | 9 | 0.470 |
Why?
| | Stroke | 4 | 2016 | 332 | 0.460 |
Why?
| | Risk Factors | 8 | 2019 | 2701 | 0.450 |
Why?
| | Ventricular Function, Right | 4 | 2013 | 148 | 0.450 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 58 | 0.430 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 2010 | 105 | 0.420 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 1999 | 323 | 0.420 |
Why?
| | Staphylococcal Infections | 2 | 2013 | 59 | 0.420 |
Why?
| | Pulsatile Flow | 1 | 2008 | 30 | 0.410 |
Why?
| | Abnormalities, Multiple | 2 | 2010 | 382 | 0.400 |
Why?
| | Vasopressins | 1 | 2008 | 10 | 0.400 |
Why?
| | Shock | 1 | 2008 | 19 | 0.400 |
Why?
| | Ultrasonography, Prenatal | 3 | 2018 | 260 | 0.390 |
Why?
| | Cerebral Hemorrhage | 2 | 1999 | 77 | 0.390 |
Why?
| | Ontario | 6 | 2019 | 1749 | 0.390 |
Why?
| | Disease Management | 3 | 2019 | 188 | 0.390 |
Why?
| | Models, Animal | 1 | 2008 | 161 | 0.380 |
Why?
| | Survivors | 3 | 2001 | 308 | 0.380 |
Why?
| | Patient Care Team | 1 | 2008 | 138 | 0.370 |
Why?
| | Prospective Studies | 8 | 2017 | 2408 | 0.340 |
Why?
| | Brain Neoplasms | 4 | 2012 | 1093 | 0.340 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 25 | 0.340 |
Why?
| | Sheep | 1 | 2005 | 83 | 0.330 |
Why?
| | Morbidity | 4 | 2019 | 94 | 0.330 |
Why?
| | Ductus Arteriosus | 1 | 2005 | 31 | 0.330 |
Why?
| | Liver | 1 | 2008 | 351 | 0.320 |
Why?
| | Transfection | 1 | 2005 | 337 | 0.310 |
Why?
| | Oxygen | 4 | 2008 | 306 | 0.310 |
Why?
| | Kidney | 1 | 2008 | 478 | 0.300 |
Why?
| | Cause of Death | 3 | 2014 | 167 | 0.300 |
Why?
| | Equipment Design | 3 | 2015 | 211 | 0.300 |
Why?
| | Sildenafil Citrate | 5 | 2012 | 11 | 0.290 |
Why?
| | Purines | 5 | 2012 | 23 | 0.290 |
Why?
| | Heart Septum | 1 | 2003 | 43 | 0.280 |
Why?
| | Endocarditis, Bacterial | 1 | 2003 | 19 | 0.280 |
Why?
| | Catheter Ablation | 1 | 2003 | 62 | 0.280 |
Why?
| | Echocardiography, Transesophageal | 1 | 2003 | 58 | 0.280 |
Why?
| | Combined Modality Therapy | 7 | 2017 | 507 | 0.280 |
Why?
| | Streptococcal Infections | 1 | 2003 | 43 | 0.280 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2014 | 148 | 0.260 |
Why?
| | Blood Pressure | 4 | 2008 | 309 | 0.260 |
Why?
| | Antihypertensive Agents | 2 | 2016 | 54 | 0.260 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2002 | 101 | 0.250 |
Why?
| | Ventricular Pressure | 2 | 2012 | 43 | 0.250 |
Why?
| | Urologic Neoplasms | 1 | 2001 | 4 | 0.250 |
Why?
| | Ultrasonography | 2 | 2017 | 628 | 0.250 |
Why?
| | Rhabdomyosarcoma | 2 | 2001 | 74 | 0.240 |
Why?
| | Survival Analysis | 5 | 2015 | 601 | 0.240 |
Why?
| | Lung Transplantation | 3 | 2018 | 90 | 0.230 |
Why?
| | Pulmonary Circulation | 2 | 2016 | 154 | 0.230 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 1999 | 5 | 0.220 |
Why?
| | Infant, Premature, Diseases | 2 | 2015 | 179 | 0.220 |
Why?
| | Vitamin K Deficiency | 1 | 1999 | 6 | 0.220 |
Why?
| | Vitamin K | 1 | 1999 | 15 | 0.220 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2017 | 62 | 0.220 |
Why?
| | Infertility, Male | 1 | 1999 | 24 | 0.220 |
Why?
| | Lung | 3 | 2016 | 809 | 0.220 |
Why?
| | Endothelium-Dependent Relaxing Factors | 2 | 2016 | 2 | 0.220 |
Why?
| | Spermatozoa | 1 | 1999 | 43 | 0.220 |
Why?
| | Fertility | 1 | 1999 | 36 | 0.210 |
Why?
| | Ependymoma | 1 | 2001 | 190 | 0.200 |
Why?
| | Age Factors | 5 | 2017 | 1483 | 0.200 |
Why?
| | Waiting Lists | 3 | 2015 | 91 | 0.200 |
Why?
| | Antineoplastic Agents | 2 | 2001 | 517 | 0.200 |
Why?
| | von Willebrand Diseases | 1 | 2018 | 53 | 0.200 |
Why?
| | Orbital Neoplasms | 1 | 1997 | 15 | 0.200 |
Why?
| | Platelet Count | 3 | 2018 | 123 | 0.190 |
Why?
| | Decompression, Surgical | 1 | 2018 | 29 | 0.190 |
Why?
| | Shock, Septic | 1 | 2018 | 24 | 0.190 |
Why?
| | Time Factors | 6 | 2018 | 2209 | 0.190 |
Why?
| | Intensive Care Units | 1 | 2018 | 77 | 0.190 |
Why?
| | United States | 3 | 2015 | 742 | 0.190 |
Why?
| | Lymphangiectasis | 1 | 2017 | 9 | 0.190 |
Why?
| | Hemangioma, Cavernous | 1 | 1997 | 2 | 0.190 |
Why?
| | Catheterization, Peripheral | 1 | 2018 | 72 | 0.190 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1997 | 37 | 0.180 |
Why?
| | Vascular Surgical Procedures | 1 | 2018 | 89 | 0.180 |
Why?
| | Decision Making | 1 | 2019 | 190 | 0.180 |
Why?
| | Cyanosis | 1 | 2017 | 24 | 0.180 |
Why?
| | Thrombelastography | 1 | 2017 | 21 | 0.180 |
Why?
| | Thrombectomy | 1 | 2016 | 15 | 0.180 |
Why?
| | Neuroblastoma | 2 | 2001 | 273 | 0.180 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 97 | 0.170 |
Why?
| | Blood Coagulation | 1 | 2017 | 57 | 0.170 |
Why?
| | Mutation | 1 | 2005 | 2078 | 0.170 |
Why?
| | Heart Rate | 2 | 2007 | 178 | 0.170 |
Why?
| | Central Nervous System Neoplasms | 2 | 2012 | 134 | 0.170 |
Why?
| | Hospitalization | 1 | 2019 | 408 | 0.170 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2018 | 144 | 0.170 |
Why?
| | Vasodilation | 1 | 2016 | 67 | 0.170 |
Why?
| | Aortography | 1 | 2015 | 29 | 0.170 |
Why?
| | Feasibility Studies | 3 | 2019 | 352 | 0.170 |
Why?
| | Head | 1 | 2016 | 66 | 0.170 |
Why?
| | Respiratory Function Tests | 2 | 2014 | 260 | 0.160 |
Why?
| | Pulmonary Veins | 1 | 2017 | 149 | 0.160 |
Why?
| | Hemoglobins | 2 | 2008 | 128 | 0.160 |
Why?
| | Body Height | 1 | 2016 | 175 | 0.160 |
Why?
| | Mass Spectrometry | 2 | 2013 | 119 | 0.160 |
Why?
| | Testicular Neoplasms | 1 | 1995 | 21 | 0.160 |
Why?
| | Cardiopulmonary Resuscitation | 2 | 2007 | 84 | 0.160 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1995 | 30 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2016 | 173 | 0.150 |
Why?
| | Epinephrine | 2 | 2012 | 37 | 0.150 |
Why?
| | Multivariate Analysis | 4 | 2017 | 422 | 0.150 |
Why?
| | Cardiopulmonary Bypass | 2 | 2008 | 138 | 0.150 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 224 | 0.150 |
Why?
| | Body Mass Index | 1 | 2016 | 343 | 0.150 |
Why?
| | Growth Disorders | 1 | 2016 | 163 | 0.150 |
Why?
| | Endocarditis | 1 | 2013 | 10 | 0.150 |
Why?
| | Compassionate Use Trials | 1 | 2013 | 1 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 574 | 0.140 |
Why?
| | Body Size | 1 | 2013 | 24 | 0.140 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 12 | 0.140 |
Why?
| | Heart Function Tests | 1 | 2013 | 24 | 0.140 |
Why?
| | Multiple Organ Failure | 1 | 2013 | 25 | 0.140 |
Why?
| | Mortality | 1 | 2013 | 65 | 0.140 |
Why?
| | Cardiomyopathies | 2 | 2011 | 111 | 0.140 |
Why?
| | Biopsy | 1 | 2014 | 334 | 0.140 |
Why?
| | Heart Failure, Systolic | 1 | 2012 | 1 | 0.140 |
Why?
| | Postoperative Care | 3 | 2009 | 142 | 0.140 |
Why?
| | Blood Gas Analysis | 1 | 2012 | 45 | 0.130 |
Why?
| | Noninvasive Ventilation | 1 | 2012 | 17 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2013 | 286 | 0.130 |
Why?
| | Risk | 1 | 2013 | 252 | 0.130 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2012 | 37 | 0.130 |
Why?
| | Cardiotonic Agents | 1 | 2012 | 38 | 0.130 |
Why?
| | Norepinephrine | 1 | 2012 | 31 | 0.130 |
Why?
| | Electrocardiography | 2 | 2013 | 215 | 0.130 |
Why?
| | Comorbidity | 1 | 2013 | 292 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2013 | 132 | 0.130 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 58 | 0.130 |
Why?
| | Linear Models | 4 | 2017 | 368 | 0.130 |
Why?
| | Blood Flow Velocity | 1 | 2013 | 230 | 0.130 |
Why?
| | Gestational Age | 3 | 2018 | 536 | 0.130 |
Why?
| | Infusions, Intravenous | 2 | 2012 | 176 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 812 | 0.120 |
Why?
| | Prevalence | 1 | 2014 | 774 | 0.120 |
Why?
| | Stem Cell Transplantation | 1 | 2012 | 115 | 0.120 |
Why?
| | Hemorrhage | 1 | 2013 | 174 | 0.120 |
Why?
| | Liver Diseases | 1 | 2013 | 138 | 0.120 |
Why?
| | Ventricular Remodeling | 1 | 2012 | 79 | 0.120 |
Why?
| | Incidence | 1 | 2014 | 859 | 0.120 |
Why?
| | Animals | 6 | 2012 | 7875 | 0.120 |
Why?
| | Myocarditis | 1 | 2011 | 40 | 0.120 |
Why?
| | Exercise Tolerance | 1 | 2011 | 79 | 0.120 |
Why?
| | Palliative Care | 2 | 2010 | 252 | 0.120 |
Why?
| | Neoplasms | 1 | 2001 | 1145 | 0.120 |
Why?
| | Radiography | 1 | 2012 | 504 | 0.120 |
Why?
| | Nervous System Diseases | 1 | 2012 | 160 | 0.120 |
Why?
| | Swine | 2 | 2008 | 395 | 0.110 |
Why?
| | Medical Records | 1 | 2010 | 84 | 0.110 |
Why?
| | Administration, Oral | 1 | 2010 | 244 | 0.110 |
Why?
| | Practice Guidelines as Topic | 4 | 2017 | 482 | 0.110 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2011 | 92 | 0.110 |
Why?
| | Disease Progression | 3 | 2019 | 694 | 0.110 |
Why?
| | Postoperative Complications | 3 | 2015 | 1111 | 0.110 |
Why?
| | Angiography | 2 | 2013 | 92 | 0.100 |
Why?
| | Hospital Departments | 1 | 2008 | 7 | 0.100 |
Why?
| | Pediatrics | 4 | 2015 | 997 | 0.100 |
Why?
| | Safety | 1 | 2008 | 99 | 0.100 |
Why?
| | Liver Function Tests | 1 | 2008 | 30 | 0.100 |
Why?
| | Medical Records Systems, Computerized | 1 | 2008 | 20 | 0.100 |
Why?
| | Kidney Function Tests | 1 | 2008 | 51 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2008 | 88 | 0.100 |
Why?
| | Pregnancy | 3 | 2018 | 1895 | 0.100 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 751 | 0.100 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2008 | 33 | 0.100 |
Why?
| | Arrhythmias, Cardiac | 1 | 2008 | 105 | 0.100 |
Why?
| | Cerebrum | 1 | 2008 | 29 | 0.100 |
Why?
| | Learning | 1 | 2008 | 94 | 0.100 |
Why?
| | Pilot Projects | 2 | 2007 | 508 | 0.090 |
Why?
| | Energy Intake | 1 | 2008 | 141 | 0.090 |
Why?
| | Respiratory Transport | 1 | 2006 | 3 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2001 | 293 | 0.090 |
Why?
| | Dopamine | 1 | 2006 | 32 | 0.090 |
Why?
| | Tetrazoles | 1 | 2006 | 7 | 0.090 |
Why?
| | Epoprostenol | 1 | 2006 | 25 | 0.090 |
Why?
| | Blood Platelets | 1 | 2008 | 246 | 0.090 |
Why?
| | Oximetry | 4 | 2008 | 65 | 0.090 |
Why?
| | Pyridines | 1 | 2006 | 39 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 939 | 0.090 |
Why?
| | Energy Metabolism | 1 | 2008 | 195 | 0.090 |
Why?
| | Brain Chemistry | 1 | 2006 | 45 | 0.090 |
Why?
| | Health Personnel | 1 | 2008 | 169 | 0.090 |
Why?
| | Cohort Studies | 4 | 2015 | 2065 | 0.080 |
Why?
| | Dinoprostone | 1 | 2005 | 20 | 0.080 |
Why?
| | Spleen | 1 | 2006 | 95 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2006 | 113 | 0.080 |
Why?
| | Nebulizers and Vaporizers | 1 | 2006 | 81 | 0.080 |
Why?
| | Neoplasm Staging | 2 | 1997 | 248 | 0.080 |
Why?
| | DNA Primers | 1 | 2005 | 211 | 0.080 |
Why?
| | Administration, Inhalation | 2 | 2016 | 186 | 0.080 |
Why?
| | Fetus | 2 | 2018 | 255 | 0.080 |
Why?
| | Global Health | 2 | 2019 | 239 | 0.080 |
Why?
| | Blotting, Western | 1 | 2005 | 327 | 0.080 |
Why?
| | Walking | 1 | 2005 | 65 | 0.080 |
Why?
| | Proteins | 1 | 2008 | 436 | 0.080 |
Why?
| | Patient Care Management | 1 | 2004 | 9 | 0.080 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2007 | 197 | 0.070 |
Why?
| | North America | 2 | 2017 | 146 | 0.070 |
Why?
| | Base Sequence | 1 | 2005 | 853 | 0.070 |
Why?
| | Animals, Newborn | 1 | 2005 | 459 | 0.070 |
Why?
| | Patient Care | 1 | 2003 | 17 | 0.070 |
Why?
| | Viridans Streptococci | 1 | 2003 | 13 | 0.070 |
Why?
| | Respiration, Artificial | 3 | 2015 | 217 | 0.070 |
Why?
| | Aortic Valve Insufficiency | 1 | 2003 | 28 | 0.070 |
Why?
| | Mitral Valve Insufficiency | 1 | 2003 | 34 | 0.070 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2003 | 35 | 0.070 |
Why?
| | Heart Arrest | 1 | 2004 | 91 | 0.070 |
Why?
| | Growth | 1 | 2003 | 84 | 0.070 |
Why?
| | Pulmonary Valve | 1 | 2003 | 85 | 0.070 |
Why?
| | Postoperative Period | 3 | 2008 | 157 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2003 | 67 | 0.070 |
Why?
| | Pulmonary Valve Insufficiency | 1 | 2003 | 68 | 0.070 |
Why?
| | Observer Variation | 1 | 2003 | 266 | 0.070 |
Why?
| | Infant, Newborn, Diseases | 1 | 2004 | 135 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 406 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2016 | 771 | 0.070 |
Why?
| | Medical Oncology | 1 | 2003 | 112 | 0.070 |
Why?
| | Oxygen Inhalation Therapy | 2 | 2015 | 37 | 0.060 |
Why?
| | Heart | 1 | 2003 | 182 | 0.060 |
Why?
| | Internet | 1 | 2003 | 185 | 0.060 |
Why?
| | Breath Tests | 1 | 2002 | 117 | 0.060 |
Why?
| | Graft Occlusion, Vascular | 1 | 2001 | 8 | 0.060 |
Why?
| | Child Welfare | 1 | 2003 | 144 | 0.060 |
Why?
| | Rabbits | 2 | 2012 | 289 | 0.060 |
Why?
| | Myocardial Contraction | 2 | 2012 | 102 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2017 | 1307 | 0.060 |
Why?
| | Carcinoma, Renal Cell | 1 | 2001 | 28 | 0.060 |
Why?
| | Achondroplasia | 1 | 2001 | 4 | 0.060 |
Why?
| | Nuclear Family | 1 | 2001 | 43 | 0.060 |
Why?
| | Spinal Cord Compression | 1 | 2001 | 19 | 0.060 |
Why?
| | Germinoma | 1 | 2001 | 46 | 0.060 |
Why?
| | Protease Inhibitors | 1 | 2000 | 21 | 0.060 |
Why?
| | Educational Status | 1 | 2001 | 117 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2001 | 128 | 0.060 |
Why?
| | Pancreatic Elastase | 1 | 2000 | 23 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2012 | 931 | 0.060 |
Why?
| | Echocardiography, Doppler | 2 | 2013 | 199 | 0.060 |
Why?
| | Pyrroles | 1 | 2000 | 32 | 0.060 |
Why?
| | Sulfonamides | 1 | 2000 | 52 | 0.060 |
Why?
| | Wilms Tumor | 1 | 2001 | 109 | 0.060 |
Why?
| | Sperm Count | 1 | 1999 | 3 | 0.060 |
Why?
| | Sperm Motility | 1 | 1999 | 10 | 0.060 |
Why?
| | Follicle Stimulating Hormone | 1 | 1999 | 11 | 0.060 |
Why?
| | Luteinizing Hormone | 1 | 1999 | 15 | 0.060 |
Why?
| | Fetal Death | 1 | 1999 | 60 | 0.050 |
Why?
| | Testosterone | 1 | 1999 | 41 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2014 | 1339 | 0.050 |
Why?
| | Fatal Outcome | 1 | 1999 | 226 | 0.050 |
Why?
| | Intelligence | 1 | 2001 | 230 | 0.050 |
Why?
| | Biomarkers | 1 | 2002 | 669 | 0.050 |
Why?
| | Hemorheology | 1 | 2018 | 6 | 0.050 |
Why?
| | Adult | 2 | 1999 | 6244 | 0.050 |
Why?
| | von Willebrand Factor | 1 | 2018 | 73 | 0.050 |
Why?
| | Orbit Evisceration | 1 | 1997 | 3 | 0.050 |
Why?
| | Health Status | 1 | 2001 | 296 | 0.050 |
Why?
| | Femoral Artery | 1 | 2018 | 35 | 0.050 |
Why?
| | Thrombocytopenia | 1 | 2018 | 104 | 0.050 |
Why?
| | Device Approval | 1 | 2017 | 4 | 0.050 |
Why?
| | Fibrin | 1 | 2017 | 9 | 0.050 |
Why?
| | Fibrinogen | 1 | 2017 | 43 | 0.050 |
Why?
| | Hematocrit | 1 | 2017 | 44 | 0.050 |
Why?
| | Spectroscopy, Near-Infrared | 2 | 2007 | 21 | 0.040 |
Why?
| | Canada | 1 | 2003 | 2154 | 0.040 |
Why?
| | Cranial Irradiation | 1 | 1997 | 98 | 0.040 |
Why?
| | Cerebral Arterial Diseases | 1 | 2016 | 37 | 0.040 |
Why?
| | Growth Charts | 1 | 2016 | 24 | 0.040 |
Why?
| | Monitoring, Physiologic | 2 | 2008 | 168 | 0.040 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 11 | 0.040 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2015 | 10 | 0.040 |
Why?
| | Infant Mortality | 1 | 2018 | 167 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2015 | 43 | 0.040 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2015 | 22 | 0.040 |
Why?
| | Young Adult | 2 | 2016 | 2592 | 0.040 |
Why?
| | Equipment Safety | 1 | 2015 | 6 | 0.040 |
Why?
| | Sex Factors | 1 | 2017 | 466 | 0.040 |
Why?
| | Ischemic Attack, Transient | 1 | 2015 | 21 | 0.040 |
Why?
| | Shear Strength | 1 | 2014 | 7 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2015 | 75 | 0.040 |
Why?
| | Elastic Modulus | 1 | 2014 | 23 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2014 | 74 | 0.040 |
Why?
| | Stents | 2 | 2009 | 181 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 149 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 1192 | 0.040 |
Why?
| | Elasticity Imaging Techniques | 1 | 2014 | 45 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2015 | 445 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2014 | 370 | 0.040 |
Why?
| | Logistic Models | 1 | 2015 | 508 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 4 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 17 | 0.030 |
Why?
| | Collagenases | 1 | 2012 | 7 | 0.030 |
Why?
| | Constriction | 1 | 2012 | 10 | 0.030 |
Why?
| | Connective Tissue Growth Factor | 1 | 2012 | 17 | 0.030 |
Why?
| | Receptors, Endothelin | 1 | 2012 | 13 | 0.030 |
Why?
| | Endothelin-1 | 1 | 2012 | 25 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2012 | 109 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2012 | 20 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2013 | 88 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2012 | 81 | 0.030 |
Why?
| | Ligation | 1 | 2012 | 46 | 0.030 |
Why?
| | Collagen | 1 | 2012 | 152 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 122 | 0.030 |
Why?
| | Elasticity | 1 | 2011 | 41 | 0.030 |
Why?
| | Infant, Premature | 1 | 2015 | 566 | 0.030 |
Why?
| | Shock, Cardiogenic | 1 | 2011 | 9 | 0.030 |
Why?
| | Body Surface Area | 1 | 2011 | 31 | 0.030 |
Why?
| | Brain | 1 | 2001 | 1563 | 0.030 |
Why?
| | Acute Disease | 1 | 2012 | 426 | 0.030 |
Why?
| | Age of Onset | 1 | 2012 | 453 | 0.030 |
Why?
| | Myocardium | 1 | 2012 | 264 | 0.030 |
Why?
| | Systole | 1 | 2010 | 109 | 0.030 |
Why?
| | Diastole | 1 | 2010 | 103 | 0.030 |
Why?
| | Chronic Disease | 1 | 2012 | 487 | 0.030 |
Why?
| | Angioplasty, Balloon | 1 | 2009 | 62 | 0.030 |
Why?
| | Reoperation | 1 | 2009 | 439 | 0.020 |
Why?
| | Biological Transport | 1 | 2008 | 167 | 0.020 |
Why?
| | Delivery Rooms | 1 | 2007 | 2 | 0.020 |
Why?
| | Perioperative Care | 1 | 2008 | 51 | 0.020 |
Why?
| | Naloxone | 1 | 2007 | 13 | 0.020 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2007 | 5 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 2008 | 127 | 0.020 |
Why?
| | Asphyxia Neonatorum | 1 | 2007 | 36 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2007 | 50 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2007 | 66 | 0.020 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2007 | 79 | 0.020 |
Why?
| | Partial Pressure | 1 | 2006 | 12 | 0.020 |
Why?
| | Hypothermia, Induced | 1 | 2007 | 79 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2010 | 1195 | 0.020 |
Why?
| | Nutritional Requirements | 1 | 2008 | 177 | 0.020 |
Why?
| | Cerebrovascular Circulation | 1 | 2008 | 186 | 0.020 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2007 | 177 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2007 | 305 | 0.020 |
Why?
| | Emergency Treatment | 1 | 2004 | 39 | 0.020 |
Why?
| | Germany | 1 | 2003 | 50 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2004 | 92 | 0.020 |
Why?
| | Vascular Patency | 1 | 2001 | 25 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2001 | 111 | 0.020 |
Why?
| | Monocrotaline | 1 | 2000 | 7 | 0.010 |
Why?
| | Central Nervous System | 1 | 2001 | 91 | 0.010 |
Why?
| | Magnetic Resonance Angiography | 1 | 2001 | 169 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 420 | 0.010 |
Why?
| | Rats | 1 | 2000 | 1289 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2001 | 2610 | 0.010 |
Why?
|
|
Humpl's networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|